Bristol-Myers Squibb Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Jefferies Raises Price Target on Bristol-Myers Squibb (BMY) Following 3Q
October 28, 2016 8:00 AM EDTJefferies reiterated a Hold rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target to $58.00 (from $54.00), following the company's 3Q. Non-GAAP operating expenses are now expected to be roughly flat through 2020, relative to 2016 levels as part of the company's plan... More
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 12c; Boosts FY16 Outlook; Approves New $3B Stock Buyback Plan
October 27, 2016 7:00 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $4.83 billion versus the consensus estimate of $4.79 billion.
Bristol-Myers Squibb today announced its Board of Directors approved a new $3 billion repurchase... More
